<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268762</url>
  </required_header>
  <id_info>
    <org_study_id>Argatroban+TPA 02-121B</org_study_id>
    <secondary_id>P50NS44227 project #2</secondary_id>
    <nct_id>NCT00268762</nct_id>
  </id_info>
  <brief_title>Argatroban Stroke Treatment - A Pilot Safety Study</brief_title>
  <official_title>A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is the combination of low doses of argatroban in combination with rt-PA safe, and does it
      increase recanalization in patients with acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with acute ischemic stroke who qualify for IV rt-PA under accepted guidelines,
      and who have an occluded middle cerebral artery documented on TCD, receive standard dose IV
      rt-PA and a bolus and 48 hour infusion of argatroban aimed at prolonging the aPTT 1.75 X
      baseline. Follow up CT scanning and TCD every 30 minutes for 2 hours and then daily will
      determine the incidence of hemorrhage, recanalization and reocclusion, and serial
      neurological exam will determine the clinical outcome. For patients without temporal windows,
      a baseline CT-Angiogram (CTA) demonstrating arterial occlusion can also be enrolled. In those
      patients, a follow-up CTA (24-36 hours) will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic and Radiographic Intracerebral Hemorrhage</measure>
    <time_frame>Within 7 days of enrollment</time_frame>
    <description>Significant intracerebral hemorrhage as defined by either:
Symptomatic intracerebral hemorrhage or
Parenchymal hematoma type 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Complete Recanalization at 2 Hours Post tPA Bolus</measure>
    <time_frame>2 hours complete recanalization post tPA bolus</time_frame>
    <description>Complete Recanalization as measured by either transcranial Doppler Ultrasound at 2 hours post tPA bolus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Complete Recanalization at 24 Hours Post tPA Bolus</measure>
    <time_frame>24 hours from tPA bolus</time_frame>
    <description>Complete recanalization at 24 hours post tPA bolus as measured by either transcranial Doppler ultrasound or CT-Angiography.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Argatroban IV Infusion 1 mcg/kg/min for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>argatroban</intervention_name>
    <description>Argatroban IV Infusion at 1mcg/kg/min for 48 hours.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke symptoms with onset ≤ 3 hours*.

               -  *or&lt;4.5 hours according to local standard of care. Symptoms must be distinguished
                  from another ischemic event such as syncope, seizure, migraine, and hypoglycemia.
                  If the patient reports awakening with the event, the time of onset should be
                  considered as last time the patient (or a witness to the patient's condition)
                  considered herself/himself normal.

          -  18-85 years of age.

          -  A clot causing complete or partial occlusion (TIBI 0, 1, 2, or 3) via TCD in any one
             of the following areas: distal iternal carotid artery (ICA), Meddle cerebral artery
             (MCA - M1 or M2), posterior cerebral arteral (ICA - P1 or P2), distal vertebral or
             basilar occlusions. TCD must be abnormal prior to the start of Argatroban. For
             patients without temporal windows (or in centers without emergent access to TCD), an
             abnormal CTA is required for enrollment (TIMI 0 or 1).

          -  Females of childbearing potential must have a negative serum pregnancy test prior
             administration of argatroban.

          -  Signed informed consent by the patient or the patient's legal representative.

          -  Meet criteria for rt-PA therapy.

        Exclusion Criteria:

          -  Evidence of intracranial hemorrhage on baseline CT scan or non-vascular cause of
             neurologic deficit.

          -  National institute health stroke scale (NIHSS) Level of Consciousness score ≥2.

          -  Baseline (immediately pre-Argatroban) NIHSS ≤ 5 or patient with rapidly resolving
             deficit or rapidly improving symptoms consistent with TPA.

          -  Baseline NIHSS ≥15 for right hemisphere strokes and ≥20 for left hemisphere strokes.

          -  Pre-existing disability with modified rankin scale (mRS) ≥ 2.

          -  CT scan findings of hypoattenuation of the x-ray signal (hypodensity)involving ≥ 1/2
             of the MCA territory.

          -  Any evidence of clinically significant bleeding, or known coagulopathy.

          -  Patients currently on warfarin, with an elevated INR ≥ 1.5.

          -  Patients currently or within previous 48 hrs. on heparin with an elevated aPTT greater
             than the upper limit of normal.

          -  Heparin flush required for an IV line. Line flushes with saline only.

          -  History of ICH or significant bleeding episode within the 3 months before study
             enrollment.

          -  Major surgery or serious trauma within the last 6 weeks.

          -  Patients who have had an arterial puncture at a non-compressible site, biopsy of
             parenchymal organ, or lumbar puncture within the last 2 weeks.

          -  Previous stroke, myocardial infarction, post myocardial infarction pericarditis,
             intracranial surgery, or significant head trauma within 3 months of baseline.

          -  Uncontrolled hypertension.

          -  Alcohol and/or substance abuse that would increase the risk of hemorrhage in the
             opinion of the investigator.

          -  Surgical intervention anticipated within the next 7 days.

          -  Hepatic dysfunction, defined by liver function tests greater than 3 times upper limit
             of normal at baseline, specifically serum glutamic-oxaloacetic transaminase (SGOT) and
             serum glutamic-pyruvic transaminase (SGPT).

          -  Abnormal blood glucose

          -  History of primary or metastatic brain tumor.

          -  Severe mental deficit prior to onset of stroke such as organic brain disorder,
             schizophrenia, etc.

          -  Concurrent severe neurologic disorder, such as seizure at onset of stroke or
             uncontrolled seizure disorder that complicates diagnosis of acute ischemic stroke.

          -  Current platelet count&lt; 100,000/mm3.

          -  Life expectancy &lt;3 months in the opinion of the investigator.

          -  Need to be on concomitant (i.e, during the Argatroban infusion) anticoagulants other
             than Argatroban, including any form of heparin, unfractionated heparin (UFH), low
             molecular weight heparin (LMWH), defibrinogenating agent, dextran, other direct
             thrombin inhibitors or thrombolytic agents, glycoprotein llb/llla (GPIIb/IIIa) or
             warfarin.(Caveat: If these anticoagulants can be deferred for 48 hours, then they can
             be included).

          -  Participated in investigational study within 30 days before the first dose of study
             medication.

          -  Hypersensitivity to Argatroban or its agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D. Barreto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital-Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Southwest Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.houstonstroke.com</url>
    <description>Introduction of the staff and facility of the stroke team, explanation of stroke, types of strokes, treatment, risk factors, recovery, clinical trials, and contact information.</description>
  </link>
  <results_reference>
    <citation>Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moyé LA, Alexandrov AV, Grotta JC. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006 Aug;63(8):1057-62.</citation>
    <PMID>16908730</PMID>
  </results_reference>
  <results_reference>
    <citation>Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, Wu TC, Sisson A, Pandurengan R, Chen Z, Rahbar MH, Balucani C, Barlinn K, Sugg RM, Garami Z, Tsivgoulis G, Gonzales NR, Savitz SI, Mikulik R, Demchuk AM, Grotta JC. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012 Mar;43(3):770-5. doi: 10.1161/STROKEAHA.111.625574. Epub 2012 Jan 5.</citation>
    <PMID>22223235</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <results_first_submitted>August 20, 2012</results_first_submitted>
  <results_first_submitted_qc>August 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2012</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Andrew Barreto</investigator_full_name>
    <investigator_title>Assistant Professor - Neurology</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>thrombin inhibition</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>bleeding</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first enrollment: May 6, 2003 Date of last enrollment: August 20, 2010 All patients enrolled through hospital emergency departments</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Argatroban IV bolus 100 mcg/kg bolus, followed by Argatroban IV Infusion 1 mcg/kg/min for 48 hours. Dose adjusted for target partial thromboplastin time (PTT) of 1.75 times the patient's baseline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Argatroban IV bolus 100 mcg/kg bolus, followed by Argatroban IV Infusion 1 mcg/kg/min for 48 hours. Dose adjusted for target PTT of 1.75 times the patient's baseline.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptomatic and Radiographic Intracerebral Hemorrhage</title>
        <description>Significant intracerebral hemorrhage as defined by either:
Symptomatic intracerebral hemorrhage or
Parenchymal hematoma type 2.</description>
        <time_frame>Within 7 days of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Argatroban IV Infusion 1 mcg/kg/min for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic and Radiographic Intracerebral Hemorrhage</title>
          <description>Significant intracerebral hemorrhage as defined by either:
Symptomatic intracerebral hemorrhage or
Parenchymal hematoma type 2.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="1.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Complete Recanalization at 2 Hours Post tPA Bolus</title>
        <description>Complete Recanalization as measured by either transcranial Doppler Ultrasound at 2 hours post tPA bolus.</description>
        <time_frame>2 hours complete recanalization post tPA bolus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Argatroban IV Infusion 1 mcg/kg/min for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Complete Recanalization at 2 Hours Post tPA Bolus</title>
          <description>Complete Recanalization as measured by either transcranial Doppler Ultrasound at 2 hours post tPA bolus.</description>
          <units>percent of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Complete Recanalization at 24 Hours Post tPA Bolus</title>
        <description>Complete recanalization at 24 hours post tPA bolus as measured by either transcranial Doppler ultrasound or CT-Angiography.</description>
        <time_frame>24 hours from tPA bolus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Argatroban IV Infusion 1 mcg/kg/min for 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Complete Recanalization at 24 Hours Post tPA Bolus</title>
          <description>Complete recanalization at 24 hours post tPA bolus as measured by either transcranial Doppler ultrasound or CT-Angiography.</description>
          <units>percent of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days during the study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Argatroban IV bolus 100 mcg/kg bolus, followed by Argatroban IV Infusion 1 mcg/kg/min for 48 hours. Dose adjusted for target PTT of 1.75 times the patient's baseline.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Significant laboratory abnormality</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death that occured by any of the following causes: (brain herniation or respiratory failure)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke progression or neurological worsening</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Significant intracerebral hemorrhage</sub_title>
                <description>Significant intracerebral hemorrhage defined as either:
Symptomatic intracerebral hemorrhage or
Parenchymal Hematoma - type 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cerebral edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Asymptomatic ICH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia/respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia/decrease in hemoglobin and hematocrit level</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>This includes one patient with &quot;Low Blood Pressure&quot;</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Patent Foramen Ovale</sub_title>
                <description>New diagnosis of patent foramen ovale.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Aortic valve vegetation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>New diagnosis of diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea with or without Emesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Laboratory abnormalities - Chemistries</sub_title>
                <description>Elevated: Creatinine Kinase/troponin=6; Liver Function Tests=2; blood urea nitrogen (BUN)=1; myoglobin=1 ; Bilirubin=1; Ketones=1; Serum Creatinine=1; Hypoglycemia=1</description>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Exacerbation of uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oral thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Self extubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Laboratory Abnormalities - Electrolytes</sub_title>
                <description>Hypokalemia=5; Hyperkalemia=2; Hyponatremia=3; Hypernatremia=2; Hypocalcemia=3 Hypomagnesia=1; Hypophosphatemia=2; Electrolyte disorder not-specified=1</description>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Laboratory Abnormalities - Elevated PTT &gt;100 seconds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Minimally displaced fracture of base of fifth metacarpal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hand swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic Intracranial Hemorhhage</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Agitation/lethargic/somnolent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Stroke progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neuro-worsening</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive sleepness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Visual hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Restless</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary Analysis laboratory abnormality</sub_title>
                <description>Leuko-Uria = 1 &amp; Hematuria = 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Right lung mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Coughing/gagging</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Both lung with rales</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Slight angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possible selection bias and investigators unblinded to treatment. In addition, although 60/65 patients had 24 hour recanalization data, only 47 were available at 2 hours.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew D. Barreto, MD</name_or_title>
      <organization>University of Texas Health Science Center at Houston</organization>
      <phone>713-500-7002</phone>
      <email>andrew.d.barreto@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

